

Start	Duration (min)	MDCC Agenda November 13, 2015
8:30	15	Welcome and Introductions <i>Steve Katz, Acting Chair MDCC</i>
8:45	10	Conflict of interest, committee management, general info <i>Glen Nuckolls, Executive Secretary MDCC</i>
8:55	30	<i>Eunice Kennedy Shriver</i> National Institute of Child Health and Human Development (NICHD) <i>Catherine Spong, Acting Director NICHD</i>
9:25	15	MDCC Action Plan: Member Organization Mission Landscape and Progress Monitoring <i>Glen Nuckolls</i>
9:40	45	Discussion of Action Plan mission landscape and progress monitoring <i>Committee members and meeting participants</i>
10:25	15	Break
10:40	25	MDF Patient-Centered Therapy Development Meeting Report <i>Sharon Hesterlee, Myotonic Dystrophy Foundation</i>
11:05	25	FSHD Trial Readiness Meeting Report <i>Rabi Tawil, University of Rochester</i>
11:30	10	FSHD International Research Consortium and Planning Workshop Report <i>Dan Perez, FSH Society</i>
11:40	30	FDA Biomarker Qualification Program <i>Shashi Amur, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration</i>
12:10	60	Lunch
1:10	30	Imaging Biomarkers for the Muscular Dystrophies <i>Krista Vandenborne, University of Florida</i>
1:40	30	Biochemical Biomarkers for the Duchenne Muscular Dystrophies <i>Yetrib Hathout, Children's National Medical Center, DC</i>
2:10	45	Discussion of the development and qualification of biomarkers and outcome measures for the muscular dystrophies <i>MDCC members and meeting participants</i>
2:55	15	Break
3:10	25	NIH Office of Rare Disease Research <i>Petra Kaufmann, Director ORDR, NCATS</i>
3:35	35	Comments from the public, in the room and calling in
4:10	10	Vote on nomination of MDCC Chair for 2016-2017
4:20	10	Summary of action items, closing remarks <i>Steve Katz</i>
4:30		Adjourn